(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.21%.
Veru's earnings in 2025 is -$32,710,409.On average, 6 Wall Street analysts forecast VERU's earnings for 2026 to be -$27,160,362, with the lowest VERU earnings forecast at -$34,457,722, and the highest VERU earnings forecast at -$21,997,564. On average, 4 Wall Street analysts forecast VERU's earnings for 2027 to be -$23,685,289, with the lowest VERU earnings forecast at -$26,561,161, and the highest VERU earnings forecast at -$20,305,443.
In 2028, VERU is forecast to generate -$7,621,134 in earnings, with the lowest earnings forecast at -$7,322,266 and the highest earnings forecast at -$7,845,285.